Stocktoria
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. 600436.SS
CN · Shanghai Stock Exchange · XSHG · stock · Healthcare · website
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | CN¥9.0B | CN¥10.8B | CN¥10.1B | CN¥8.7B |
| Gross profit | CN¥3.3B | CN¥4.6B | CN¥4.7B | CN¥4.0B |
| R&D expense | CN¥252.2M | CN¥269.6M | CN¥232.4M | CN¥230.0M |
| SG&A expense | CN¥276.5M | CN¥392.6M | CN¥653.5M | CN¥356.1M |
| Operating income | CN¥2.3B | CN¥3.4B | CN¥3.3B | CN¥2.9B |
| Interest expense | CN¥31.7M | CN¥37.6M | CN¥37.3M | CN¥38.0M |
| Income tax | CN¥394.5M | CN¥543.2M | CN¥517.8M | CN¥454.8M |
| Net income | CN¥2.2B | CN¥3.0B | CN¥2.8B | CN¥2.5B |
| EPS (diluted) | CN¥3.58 | CN¥4.93 | CN¥4.64 | CN¥4.10 |
| Operating cash flow | CN¥77.0M | CN¥1.3B | CN¥2.2B | CN¥6.9B |
| Free cash flow | -CN¥262.8M | CN¥245.4M | CN¥2.1B | CN¥6.7B |
| Cash & equivalents | CN¥1.3B | CN¥1.5B | CN¥1.2B | CN¥2.5B |
| Inventory | CN¥6.7B | CN¥5.0B | CN¥3.4B | CN¥2.6B |
| Total assets | CN¥17.6B | CN¥17.5B | CN¥17.1B | CN¥14.6B |
| Total debt | CN¥1.1B | CN¥1.1B | CN¥1.2B | CN¥1.1B |
| Total liabilities | CN¥2.5B | CN¥2.7B | CN¥3.2B | CN¥2.8B |
| Shareholders' equity | CN¥14.5B | CN¥14.3B | CN¥13.4B | CN¥11.3B |
Growth · year-over-year · Revenue CAGR 1.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | -16.6% | +7.3% | +15.7% | — |
| Net income growth | -27.5% | +6.4% | +13.1% | — |
| EPS growth | -27.4% | +6.2% | +13.2% | — |
| Free cash flow growth | -207.1% | -88.1% | -69.2% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · CN · as of 2025-12-31. Figures in CNY. Facts plus Stocktoria's own computed scores — not investment advice.